Successful cardiac transplantation after Novacor implantation in a HIT II-patient using heparin.
The anticoagulative management of patients tested positive for heparin-induced thrombocytopenia type II (HIT II) and requiring cardiac surgery has been difficult until now. A special challenge arises, when left ventricular assist devices have to be implanted for bridging to cardiac transplantation. We report on the anticoagulative management of such a patient, based on the consideration of HIT II-pathophysiology and using heparin for Novacor LVAD implantation and cardiac transplantation.
Christiansen
S
S
Klinik und Poliklinik fur Thorax-, Herz- und Gefässchirurgie, Westfälische Wilhelms Universität Münster, Münster, Germany.
Jahn
U R
UR
Meyer
J
J
Scheld
H H
HH
Van Aken
H
H
Hammel
D
D
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects*; D002311:Cardiomyopathy, Dilated; D004797:Enzyme-Linked Immunosorbent Assay; D016027:Heart Transplantation; D006353:Heart-Assist Devices; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D013921:Thrombocytopenia / Q000139:chemically induced*
D000925:Anticoagulants; D006493:Heparin